undamentalytics Newsletter
Sign in

Aeon Biopharma, Inc. (AEON) stock

Add to watchlist

Add holding +

NYSE: AEON NYSE Biotechnology Next results ~November 13, 2026

Aeon Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds8 adding, 5 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Share count rising (dilution): Diluted shares outstanding rose 609.2% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Aeon Biopharma, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 609.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 105% and a beta of 0.6 against the S&P 500.

Latest results

Earnings per share
-$0.02 against an average estimate of -$0.33: beat by 93.9%
Share reaction
-0.7% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500

Aeon Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.4%
  • 1 week+13.8%
  • 1 month-2.2%
  • This year-75.2%
  • 1 year-67.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-1.89

Growth

Share count change
+609.2%

Earnings

Last results
August 12, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Results
  4. Announcement
  5. Announcement
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aeon Biopharma, Inc. valuation models and calculator

No model value for Aeon Biopharma, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Aeon Biopharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.92 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.2 Left out: out of range vs price (0.18x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aeon Biopharma, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.45 +89% — 0%
Next −$0.25 +44% $472000 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −56.8% on 90 days ago. In the last 30 days, 1 analyst raised Aeon Biopharma, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Aeon Biopharma, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.05 Current fiscal year, 60 days ago: −$1.05 Current fiscal year, 30 days ago: −$0.46 Current fiscal year, 7 days ago: −$0.46 Current fiscal year, Now: −$0.45 −$0.45 Next fiscal year, 30 days ago: −$0.25 Next fiscal year, 7 days ago: −$0.27 Next fiscal year, Now: −$0.25 −$0.25

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.05−$0.25
60 days ago −$1.05−$0.27
30 days ago −$0.46−$0.25
7 days ago −$0.46$0.00
Now −$0.45$0.00

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.33 −$0.02 +93.9%
Mar 2026 −$0.44 −$0.25 +44.2%
Dec 2025 −$0.20 −$3.72 −1714.6%
Sept 2025 −$0.43 −$0.39 +9.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026134
  2. Sep 2026134
  3. Aug 202633
  4. Jul 202633

Counts of recommendations published by analysts covering Aeon Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.6%
of tradable shares
Days to cover
0.5
at average volume
Short interest, 1 month
+10%
to October 15, 2026
Held by institutions
17%
of shares
Held by insiders
46.7%
of shares
Employees
8
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202420252026 to date
Return
AEON−93%−97%−75%
Industry peers (median)−28%−5%−26%
S&P 500+25%+18%+11%
Months that ended higher
AEON33%50%27%
S&P 50075%75%46%
Largest fall from a high during the year
AEON−97%−99%−86%
S&P 500−8%−19%−9%

Worst fall since January 3, 2023: 100% from March 18, 2024 to August 21, 2026. Getting back needed a 610775% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.19 – $1.36
From 52-week high
−79.9%
vs 50-day average
+4.3%
vs 200-day average
−59.4%
Volatility (1 year)
105%
Beta vs S&P 500
0.57

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±11.2%
After a week
3 up, 9 down
typical move ±13.5%
After a month
5 up, 7 down
typical move ±29.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −0.7% +0.9% −27.5% +19.8%
May 14, 2026 −12.0% −0.4% +0.1% −18.9%
March 30, 2026 −15.1% +2.6% −19.1% −17.7%
November 14, 2025 −7.4% −0.9% −11.7% +9.6%
August 12, 2025 +21.8% +1.4% +11.3% +17.8%
May 14, 2025 −1.8% +0.6% −3.2% +81.5%
March 24, 2025 +0.1% +2.0% −13.4% −34.3%
November 13, 2024 −18.5% −0.6% −24.9% −10.3%
August 12, 2024 −4.8% +1.7% −3.8% −24.8%
May 14, 2024 −6.0% +1.7% −1.8% −19.0%
March 29, 2024 −35.9% −0.2% −27.6% −65.6%
November 13, 2023 +10.0% +1.8% +17.0% +33.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count
+609.2%
year over year

Who owns it

Funds buying and selling
Reported value
$9.2M
Institutions reporting
22
Shares held vs prior quarter
▲ 350.6%
Positions opened / closed
2 / 4

Top buyers and sellers, Q2 2026: 8 institutions bought and 5 sold ; the biggest buyer was Dauntless Investment Group, LLC (+10.0M shares) and the biggest seller Xtx Topco Ltd (−20K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Dauntless Investment Group, LLC $9M 12.5M 97.5% ▲ 394.1%
Geode Capital Management, LLC $68,556 95K 0.7% ▲ 9.5%
Vanguard Capital Management LLC $65,090 91K 0.7% 0.0%
Blue Owl Capital Holdings LP $30,494 42K 0.3% 0.0%
Formidable Asset Management, LLC $19,724 20K 0.2% 0.0%
Stonex Group Inc. $14,942 19K 0.2% New
Vanguard Fiduciary Trust Co $9,860 14K 0.1% ▼ 6.7%
LPL Financial LLC $8,277 12K 0.1% 0.0%
Citigroup Inc $5,262 7K 0.1% ▲ 885.8%
UBS Group AG $3,640 5K 0.0% ▲ 21.0%
Blackrock, Inc. $2,038 3K 0.0% 0.0%
Tower Research Capital LLC (TRC) $1,846 3K 0.0% ▲ 446.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aeon Biopharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $241,500 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $241,500 net buying
Insider Date Trade Shares Price Value
Lynch Timothy P 10% owner August 19, 2026 Buy 1,150,000 $0.21 $241,500

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 14, 2026
  • March 30, 2026
  • November 14, 2025
  • August 12, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Aeon Biopharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aeon Biopharma, Inc. in brief

What does Aeon Biopharma, Inc. do?
Aeon Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Aeon Biopharma, Inc.'s stock ticker?
Aeon Biopharma, Inc. trades under the ticker AEON on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Aeon Biopharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Dauntless Investment Group, LLC, Geode Capital Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Aeon Biopharma, Inc. stock?
Over the last 12 months, Aeon Biopharma, Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Aeon Biopharma, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aeon Biopharma, Inc. announces its own schedule.